Heart failure & cardiomyopathiesRandomised controlled trial
Trientine for hypertrophic cardiomyopathy: a phase 2 trial
- Randomised controlled trial
- phase 2
- multicentre
- placebo-controlled
Authors' conclusion
Among patients with hypertrophic cardiomyopathy, treatment with trientine resulted in a significantly greater reduction in left ventricular mass indexed to body surface area than placebo.
Study context
- Population
- Adults with hypertrophic cardiomyopathy, LV wall thickness ≥15 mm, NYHA class I–III, any left ventricular outflow tract (LVOT) gradient
- Participants
- 154 adults
- Comparison
- Trientine vs placebo
- Primary endpoint
- Change in LV mass indexed to body surface area by CMR
- Follow-up
- 52 weeks
Primary result
Change in LV mass indexed to body surface area
Between-group difference
−3.2 g/m²
95% CI −5.6 to −0.8
P = 0.009
By group
Trientine
−4.4
mean change · SD 7.7 · g/m²
Placebo
−1.5
mean change · SD 6.1 · g/m²
Trientine vs Placebo
between-group difference −3.2 g/m² (95% CI −5.6 to −0.8); P = 0.009
As reported in the abstract
Further findings
| Outcome | average causal mediated effect (g/m²) (95% CI) |
|---|---|
| Mediation via reduction in myocardial cellular mass | −3.9 (−6.8 to −0.9) |
Effect by baseline LV mass index
- Efficacy of trientine increased at higher baseline LV mass
- interaction P = .015
Safety
Adverse events
- Incidence of adverse events similar in the two groups
Original publication
Trientine for hypertrophic cardiomyopathy: a phase 2 trial. Eur Heart J. Published 15 July 2026. doi:10.1093/eurheartj/ehag512
Summarised from the published abstract; every number is checked against it